Treatment with n-3 polyunsaturated acids (PUFA) may help hemodialysis (HD) patients lower serum triglyceride levels, according to a report in Nephrology Dialysis Transplantation (2008; published online ahead of print).

Intermittent hemodialysis and continuous renal replacement therapy (CRRT) appear to lead to similar clinical outcomes for patients with acute renal failure (ARF), according to researchers who reviewed 30 randomized controlled trials and eight prospective cohort studies.

ORLANDO—Patients who moved from short daily hemodialysis (SDHD) to nocturnal daily hemodialysis (NDHD) say they experienced im-proved quality of life with a more normal lifestyle, according to a small study. Researchers presented findings here at the 2008 Annual Dialysis Conference.

ORLANDO—Arteriovenous fistulas (AVFs) should be the preferred vascular access in elderly hemodialysis (HD) patients, researchers reported at the 2008 Annual Dialysis Conference.

ORLANDO—Patients receiving home hemodialysis (HHD) are younger and more likely to be Caucasian and male than patients receiving in-center (IC) hemodialysis, according to a study presented here at the 2008 Annual Dialysis Conference. HHD patients also have lower Charlson co-morbidity scores than IC patients.

ORLANDO—A small pilot study suggests that magnesium may prevent or delay progression of vascular calcification in hemodialysis patients without a detrimental effect on bone, researchers reported here at the 2008 Annual Dialysis Conference.

ORLANDO—Patients who switched from short daily hemodialysis (SDHD) to nocturnal daily hemodialysis (NDHD) say they experienced improved quality of life with a more normal lifestyle, according to a small study presented here at the 2008 Annual Dialysis Conference.

SAN FRANCISCO—Dialysis patients hospitalized for infection, GI bleeding, or a major surgical procedure may experience a significant decline in hematocrit (Hct) levels, researchers say. The decline increases with length of stay.

HEMODIALYSIS PATIENTS infected with hepatitis C virus (HCV) have a significantly decreased requirement for erythropoietin (EPO) compared with hemodialysis patients with no history of HCV infection.

SAN FRANCISCO—Ferumoxytol, a novel IV iron replacement drug, may be more effective than oral iron in hemodialysis patients receiving anemia treatment with an erythropoiesis-stimulating agent (ESA), according to study findings presented here at Renal Week 2007.